前列腺癌疾病负担及早期防控策略分析

doi:10.3877/cma.j.issn.1674-3253.2026.03.003

前列腺癌作为全球及中国男性健康的重大威胁，其疾病负担持续加重，且存在显著的地域、城乡及年龄差异。本文通过梳理全球与中国前列腺癌的流行病学现状、发病及死亡趋势，分析疾病负担的核心特征，并系统阐述国际与国内的早期防控策略，指出当前防治工作面临的挑战，最终提出针对性建议，为推动前列腺癌精准防控、降低疾病危害提供参考。

关键词: 前列腺癌, 疾病负担, 早期筛查, 防控策略

Prostate cancer poses a major threat to the health of men globally and in China, with its disease burden continuing to increase, accompanied by significant disparities across regions, between urban and rural areas, and among different age groups. This article reviews the global and Chinese epidemiological status of prostate cancer, as well as its incidence and mortality trends, analyzes the core characteristics of the disease burden, and systematically elaborates on international and domestic early prevention and control strategies. It also identifies the challenges currently faced in prevention and treatment, and finally puts forward targeted suggestions. The aim is to provide references for promoting precise prevention and control of prostate cancer and reducing the harm caused by the disease.

Key words: Prostate cancer, Disease burden, Early screening, Prevention and control strategies

[1]	Collaborators G2C. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10512): 1565-1586. DOI: 10.1016/S0140-6736(25)01635-6.
[2]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[3]	He Y, Xu W, Xiao YT, et al. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials[J]. Sig Transduct Target Ther, 2022, 7(1): 198. DOI: 10.1038/s41392-022-01042-7.
[4]	Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050[J]. JAMA Oncol, 2023, 9(4): 465-472. DOI: 10.1001/jamaoncol.2022.7826.
[5]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[6]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[7]	瞿旻, 高旭. 2022年全球及中国前列腺癌流行状况分析[J]. 海军军医大学学报, 2025, 46(2): 229-233. DOI: 10.16781/j.CN31-2187/R.20240685.
[8]	Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location[J]. Am J Mens Health, 2018, 12(6): 1807-1823. DOI: 10.1177/1557988318798279.
[9]	Majdalany SE, Butaney M, Tinsley S, et al. Challenges of urologic oncology in low-to-middle-income countries[J]. Société Int D'urologie J, 2024, 5(5): 303-311. DOI: 10.3390/siuj5050049.
[10]	Marima R, Mbeje M, Hull R, et al. Prostate cancer disparities and management in southern Africa: insights into practices, norms and values[J]. Cancer Manag Res, 2022, 14: 3567-3579. DOI: 10.2147/CMAR.S382903.
[11]	Shete K, Ghoulian J, Hu B, et al. Genitourinary cancer care in low- and middle-income countries: disparities in incidence and access to care[J]. Société Int D’urologie J, 2024, 5(5): 330-338. DOI: 10.3390/siuj5050052.
[12]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[13]	闵淑慧, 胡依, 郭芮绮, 等. 1990—2019年中国前列腺癌疾病负担分析及趋势预测[J]. 中国肿瘤, 2023, 32(3): 171-177. DOI: 10.11735/j.issn.1004-0242.2023.03.A002.
[14]	刘哲，杨琳，胡雪华，等. 2011-2020年中国前列腺癌死亡趋势分析及2021-2030年变化趋势预测[J]. 中国肿瘤, 2025, 34(3): 171-177. DOI: 10.11735/j.issn.1004-0242.2025.03.A002
[15]	中华人民共和国国家卫生健康委员会. 2024年我国卫生健康事业发展统计公报[EB/OL]. [2025-12-02]. URL
[16]	赫捷. 2021中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2023.
[17]	潘剑, 朱耀, 戴波, 等. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217. DOI: 10.19401/j.cnki.1007-3639.2023.03.003.
[18]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
[19]	Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3): 203-213. DOI: 10.1016/j.jncc.2024.06.005.
[20]	Li H, Wang Y, Gong W, et al. Cancer survival analysis on population-based cancer registry data in Zhejiang Province, China (2018-2019)[J]. J Natl Cancer Cent, 2024, 4(1): 54-62. DOI: 10.1016/j.jncc.2023.12.003.
[21]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[22]	Wild CP, Weiderpass E,Stewart BW. World Cancer Report: Cancer research for cancer prevention[M]. Lyon: International Agency for Research on Cancer, 2020.
[23]	Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092. DOI: 10.1016/j.eururo.2012.02.054.
[24]	Dave P, Carlsson SV, Watts K. Randomized trials of PSA screening[J]. Urol Oncol, 2025, 43(1): 23-28. DOI: 10.1016/j.urolonc.2024.05.014.
[25]	Tesfai A, Norori N, Harding TA, et al. Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: a rapid review[J]. BJUI Compass, 2024, 5(5): 417-432. DOI: 10.1002/bco2.326.
[26]	Kilpeläinen TP, Tammela TL, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer[J]. Eur J Cancer, 2011, 47(18): 2698-2705. DOI: 10.1016/j.ejca.2011.06.055.
[27]	US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: us preventive services task force recommendation statement[J]. JAMA, 2018, 319(18): 1901-1913. DOI: 10.1001/jama.2018.3710.
[28]	Osses DF, Remmers S, Schröder FH, et al. Results of prostate cancer screening in a unique cohort at 19yr of follow-up[J]. Eur Urol, 2019, 75(3): 374-377. DOI: 10.1016/j.eururo.2018.10.053.
[29]	Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening[J]. J Urol, 2023, 210(1): 46-53. DOI: 10.1097/JU.0000000000003491.
[30]	程勇兵, 邱雪峰, 郭宏骞. 2025版EAU前列腺癌指南更新解读[J]. 中国肿瘤外科杂志, 2025, 17(3): 216-220. DOI: 10.3969/j.issn.1674-4136.2025.03.002.
[31]	董志伟. 中国癌症研究进展-第7卷-中国主要癌症的筛查及早诊早治[M]. 北京: 北京大学医学出版社, 2004.
[32]	中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组. 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志, 2021, 31(5): 435-440. DOI: 10.19401/j.cnki.1007-3639.2021.05.010.
[33]	赫捷, 陈万青, 李霓, 等. 中国前列腺癌筛查与早诊早治指南(2022，北京)[J]. 中国肿瘤, 2022, 31(1): 1-30. DOI: 10.11735/j.issn.1004-0242.2022.01.A001.
[34]	Ruan X, Zhang N, Wang D, et al. The impact of prostate-specific antigen screening on prostate cancer incidence and mortality in China: 13-year prospective population-based cohort study[J]. JMIR Public Health Surveill, 2024, 10: e47161. DOI: 10.2196/47161.
[35]	Kemesiene J, Nicolau C, Cholstauskas G, et al. Performance of PCA3 and TMPRSS2: ERG within the prostate cancer prevention trial risk calculator version 2 in a Lithuanian cohort[J]. Res Rep Urol, 2025, 17: 95-103. DOI: 10.2147/RRU.S511523.
[36]	Chiu ST, Cheng YT, Pu YS, et al. Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection[J]. Front Oncol, 2021, 11: 772182. DOI: 10.3389/fonc.2021.772182.
[37]	Salloum O, Taciuc IA, Dick A, et al. Diagnostic yield of fusion-guided and randomized biopsies in prostate cancer: evidence for an integrated approach[J]. Healthcare (Basel), 2025, 13(17): 2214. DOI: 10.3390/healthcare13172214.
[38]	雷必秀, 李卿. 人工智能在前列腺癌中的应用研究进展[J]. 数理医药学杂志, 2024, 37(6): 453-461. DOI: 10.12173/j.issn.1004-4337.202403093.
[39]	Shao L, Liang C, Yan Y, et al. An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer[J]. Nat Cancer, 2025, 6(10): 1621-1637. DOI: 10.1038/s43018-025-01041-x.
[40]	Tao W, Yu X, Shao J, et al. Telemedicine-enhanced lung cancer screening using mobile computed tomography unit with remote artificial intelligence assistance in underserved communities: initial results of a population cohort study in western China[J]. Telemed J E Health, 2024, 30(6): e1695-e1704. DOI: 10.1089/tmj.2023.0648.

[1]	杨轶, 廖新惠, 陈杰青, 吴建挺, 张仲富, 韩晓红, 梅红兵. 机器人辅助腹腔镜对比腹腔镜前列腺癌根治术：一项针对低、中危前列腺癌患者的回顾性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 197-201.
[2]	李俊杰, 董培, 姚成, 刘泽, 李勇. 前列腺癌免疫治疗的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 209-215.
[3]	张天阳, 王星博, 王江平. 腹腔镜下前列腺癌根治术结合尿道重建技术的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 216-220.
[4]	贺慷, 杨诚, 刘存东. 经膀胱入路单孔腹腔镜技术在泌尿外科的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 140-146.
[5]	李勇义, 赵均雄, 郭建东, 李文萱, 孟占鳌, 覃杰, 陈涵潇. 瘤体-瘤周细胞外容积模型对前列腺癌的诊断价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 56-64.
[6]	孙晓宇, 方程, 李晓阳, 吴尚融, 徐熙童, 张廷继, 李健. 1990~2021年全球膀胱癌疾病负担趋势分析及2050年预测：一项基于GBD 2021的系统分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 34-43.
[7]	蒋钟吉, 郭洪, 王东文. 近红外显影技术在前列腺癌淋巴组织显影及病理评估中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 8-14.
[8]	梅昊楠, 杨瑞, 刘修恒. 人工智能辅助病理学图像分析在前列腺癌诊断中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 1-7.
[9]	刘辉, 谢周洲, 周晓琪, 张桂豪, 江惠明, 陈南辉. 靶向SOAT1对前列腺癌的作用和机制研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 95-101.
[10]	覃桂林, 赵善超, 陈明坤. 人口老龄化背景下中国前列腺癌的疾病负担与筛查策略分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 102-107.
[11]	田超, 黄若曦, 蒋茂林, 谢崇伟, 刁鹏飞, 钟苏权, 陈东, 王航涛, 陈桂柳, 陈虞娟, 李国良. 不同亚型前列腺癌新辅助化疗后盆腔淋巴结转移的风险因素及时间分布[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 727-735.
[12]	孟维妮, 管旌旌, 刘敏, 王晓雪, 王海凤. 机器人辅助腹腔镜前列腺根治性切除术后合并多种并发症的护理体会[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 765-771.
[13]	李坤, 李洪涛, 范瑞芳, 赵丽君. 1990—2021年中国腹股沟疝、股疝和腹部疝的疾病负担分析及未来预测[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(02): 213-220.
[14]	李彬, 惠桧, 肖俏, 王晶, 詹秋里, 邱颖. 低剂量CT肺结节体积测量联合AI辅助诊断在87例肺癌早筛中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(01): 160-163.
[15]	蒋林岑, 韩坤, 郭轩宇, 李云帆, 邱仕麟, 唐永吉, 张金栋, 王德林. 免穿刺影像引导机器人前列腺根治性剜除术临床应用[J/OL]. 中华腔镜外科杂志(电子版), 2026, 19(01): 9-16.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the disease burden of prostate cancer and early prevention and control strategies

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the disease burden of prostate cancer and early prevention and control strategies